The Proprietary Mebias Discovery Platform 19Fluid


Detect fluid/solution dynamic conformation of full length GPCRs

    • Proprietary purification of native, full-length GPCR
    • Protein NMR with proprietary 19F labeling scheme to capture coupling of scaffold proteins to GPCRs

Empowers drug discovery beyond current state of the art

Platform is agnostic to therapeutic area

Successfully applied to multiple targets

    • MOR, DOR
    • S1PR1
    • β1AR, β2AR
    • Additional GPCRs have been expressed and purified as potential targets  (e.g., MLNR, A2A)